Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug;10(4):2487-2498.
doi: 10.1002/ehf2.14422. Epub 2023 Jun 6.

Rising arterial stiffness with accumulating comorbidities associates with heart failure with preserved ejection fraction

Affiliations

Rising arterial stiffness with accumulating comorbidities associates with heart failure with preserved ejection fraction

Danish Ali et al. ESC Heart Fail. 2023 Aug.

Abstract

Aims: Comorbidities play a significant role towards the pathophysiology of heart failure with preserved ejection fraction (HFpEF), characterized by abnormal macrovascular function and altered ventricular-vascular coupling. However, our understanding of the role of comorbidities and arterial stiffness in HFpEF remains incomplete. We hypothesized that HFpEF is preceded by a cumulative rise in arterial stiffness as cardiovascular comorbidities accumulate, beyond that associated with ageing.

Methods and results: Arterial stiffness was assessed using pulse wave velocity (PWV) in five groups: Group A, healthy volunteers (n = 21); Group B, patients with hypertension (n = 21); Group C, hypertension and diabetes mellitus (n = 20); Group D, HFpEF (n = 21); and Group E, HF with reduced ejection fraction (HFrEF) (n = 11). All patients were aged 70 and above. Mean PWV increased from Groups A to D (PWV 10.2, 12.2, 13.0, and 13.7 m/s, respectively) as vascular comorbidities accumulated independent of age, renal function, haemoglobin, obesity (body mass index), smoking status, and hypercholesterolaemia. HFpEF exhibited the highest PWV and HFrEF displayed near-normal levels (13.7 vs. 10 m/s, P = 0.003). PWV was inversely related to peak oxygen consumption (r = -0.304, P = 0.03) and positively correlated with left ventricular filling pressures (E/e') on echocardiography (r = -0.307, P = 0.014).

Conclusions: This study adds further support to the concept of HFpEF as a disease of the vasculature, underlined by an increasing arterial stiffness that is driven by vascular ageing and accumulating vascular comorbidities, for example, hypertension and diabetes. Reflecting a pulsatile arterial afterload associated with diastolic dysfunction and exercise capacity, PWV may provide a clinically relevant tool to identify at-risk intermediate phenotypes (e.g. pre-HFpEF) before overt HFpEF occurs.

Keywords: Arterial stiffness; Heart failure with preserved ejection fraction; Pulse wave velocity; Ventricular-arterial coupling.

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

Figure 1
Figure 1
Mean pulse wave velocity for all groups with 95% confidence intervals and pairwise P‐values from linear model results in Table 2 adjusted for age and estimated glomerular filtration rate.
Figure 2
Figure 2
Relationship between pulse wave velocity and peak VO2.

Similar articles

Cited by

References

    1. Packer M, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ, Carson P, Anand I, Doehner W, Haass M, Komajda M, Miller A, Pehrson S, Teerlink JR, Schnaidt S, Zeller C, Schnee JM, Anker SD, for the EMPEROR‐Preserved Trial Study Group . Effect of empagliflozin on worsening heart failure events in patients with heart failure and a preserved ejection fraction: the EMPEROR‐Preserved trial. Circulation. 2021; 144: 1284–1294. - PMC - PubMed
    1. Bosch A, Ott C, Jung S, Striepe K, Karg MV, Kannenkeril D, Dienemann T, Schmieder RE. How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial. Cardiovasc Diabetol. 2019; 18: 44. - PMC - PubMed
    1. Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co‐transporter 2 (SGLT2) inhibitors: a state‐of‐the‐art review. JACC Basic Transl Sci. 2020; 5: 632–644. - PMC - PubMed
    1. Mohammed SF, Borlaug BA, Roger VL, Mirzoyev SA, Rodeheffer RJ, Chirinos JA, Redfield MM. Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community‐based study. Circ Heart Fail. 2012; 5: 710–719. - PMC - PubMed
    1. Hoffman JI, Buckberg GD. The myocardial oxygen supply:demand index revisited. J Am Heart Assoc. 2014; 3: e000285. - PMC - PubMed

Publication types